TCM (524156)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me apply the Graham-Buffett lens to TCM. A ₹34 crore market cap commodity chemical company, trading at ₹45.83 against a book value of ₹47, looks like an asset play at first glance. But value investing is not buying cheap assets blindly; it is buying earning power at a discount. Here the earning power is missing. Sales have fallen 7.93%, profit growth is -32.56%, and the latest quarter shows a ₹1 crore net loss on ₹6 crore of sales. The P/E is meaningless because earnings are zero or negative. The Piotroski F-score of 3/9 is a serious red flag: it tells me the company's financial position is deteriorating, not stabilising. Return on equity of 5.75% and ROCE of 6.32% are far below what a commodity chemical maker needs to compensate for risk. There is no dividend, so I am not being paid to wait. The stock is down from the ₹81 high to the ₹45 level, but a falling price is not a margin of safety if the underlying asset value is also being eroded by losses. Graham would demand clean numbers, consistent earnings, and a clear catalyst. TCM seems to have none of these today. The book value of ₹47 is a useful cushion, but it will shrink if the company keeps losing money in a cyclical downturn. This may become a turnaround if management can arrest the sales decline and return to profitability, but I would need evidence in the next two or three quarters. For now, I classify this as an asset play, not a quality compounder. I will watch whether the balance sheet stays intact and whether the business can generate cash flow before considering an entry.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer